SGLT-2 Inhibitors: a new mechanism for glycemic control in case of T2DM. Clinical case

This clinical case report describes clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus, distal sensorimotor diabetic peripheral polyneuropathy; diabetic macroangiopathy and obliterating atherosclerosis of right anterior tibial artery, left posterior tibial artery and and left anterior tibial artery. High efficiency combined with a low risk of hypoglycaemia and convenient route of drug administration may reduce insulin administration and insulin secretagogue levels, significantly improving patient adherence to treatment and offers the possibility of better carbohydrate metabolism compensation.